CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
抗体偶联药物联合方案在肿瘤治疗中的应用：临床疗效与临床研究展望
英文原题：Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives.
查看英文原题
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
抗体-药物偶联物已成为一种前景广阔的癌症治疗手段，将细胞毒性药物的靶向递送与单克隆抗体的特异性相结合。尽管其潜力巨大，ADC仍面临耐药性和脱靶效应等局限性。为增强其疗效，ADC正越来越多地与其他治疗策略联合使用，包括免疫检查点抑制剂、化疗、小分子抑制剂、抗血管生成药物及CAR-T 细胞疗法。这些联合疗法旨在克服耐药机制、改善肿瘤靶向性并增强免疫应答。临床研究表明，此类联合方案可显著提高多种癌症的缓解率和无进展生存期。本综述探讨了抗体-药物偶联物联合疗法在癌症治疗中的机制、临床疗效、关键研究、挑战及未来前景。
展开英文摘要原文
Antibody-drug conjugates have emerged as a promising cancer treatment, combining targeted delivery of cytotoxic agents with the specificity of monoclonal antibodies. Despite their potential, ADCs face limitations such as resistance and off-target effects. To enhance their efficacy, ADCs are increasingly being combined with other therapeutic strategies, including immune checkpoint inhibitors, chemotherapy, small-molecule inhibitors, anti-angiogenic agents, and CAR-T cell therapies.
These combination therapies aim to overcome resistance mechanisms, improve tumor targeting, and boost immune responses. Clinical studies have shown that such combinations can significantly improve response rates and progression-free survival across various cancers. This review explores the mechanisms, clinical efficacy, key studies, challenges, and future perspectives of Antibody-drug conjugates combinations in cancer therapy.
论文信息
- 作者
- Shi X、Tang K、Zhang Q、Han Q、Quan L、Li Y、Cui J、Feng N
- 单位
- The Afffliated Hospital of Qingdao University, Qingdao University, Qingdao, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in pharmacology2025
- 原文标识
- PubMed 40061961 · DOI 10.3389/fphar.2025.1556245
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →